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Abstract 
Bionano-interactions can be defined as study of interactions between nanoscale entities and 
biological systems such as, but not limited to, peptides, proteins, lipids, DNA and other 
biomolecules, cells and cellular receptors and organisms including humans.  Studying bionano 
interactions is particularly useful for understanding engineered materials that have at least one 
dimension in the nanoscale. Such materials may consist of discrete particles or nanostructured 
surfaces. Much of biology functions at the nanoscale; therefore, our ability to manipulate materials 
such that they are taken up at the nanoscale, and engage biological machinery in a designed and 
purposeful manner, opens new vistas for more efficient diagnostics, therapeutics (treatments) and 
tissue regeneration, so-called nanomedicine. Additionally, this ability of nanomaterials to interact 
with and be taken up by cells allows nanomaterials to be used as probes and tools to advance our 
understanding of cellular functioning.  Yet, as a new technology, assessment of the safety of 
nanomaterials, and the applicability of existing regulatory frameworks for nanomaterials must be 
investigated in parallel with development of novel applications. The Royal Society meeting “Bionano 
interactions, new tools insights and impacts” provided an important platform for open dialogue on 
the current state of knowledge on these issues, bringing together scientists, industry, regulatory and 
legal experts to concretize existing discourse in science law and policy.  This paper summarises these 
discussions and the insights that emerged. 
Keywords:  
Nanotechnology, nanomedicine, nanosafety, nano-regulation, bio-nano interface, biomoelcule 
corona, advanced materials  
 
Background to the meeting 
Throughout the 21st century, reports about dangers and benefits of using well–established toxins, as 
well as substances that were previously considered innocuous, have been diligently examined by the 
Royal Society.  The Royal Society has pro-actively engaged in discussions regarding nanotechnologies 
since the early 2000s. It was the first major international scientific community to publish its opinion 
regarding the opportunities and challenges posed by nanotechnologies and nanomaterials for 
society.[1]  As noted in the Royal Society’s report in 2004, nanotechnology offers a fresh perspective 
for scientific understanding of the physical properties of matter. Subsequently, Royal Society 
journals have published pioneering articles concerning this emerging field, starting with inhalation 
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toxicology and exploring scientific concerns that ultrafine airborne nanoparticles might cause 
harmful effects (Figure 1), and the implications of that possible harm when applying nanotechnology 
in a diverse range of consumer applications.[2]  Those findings prompted a pause to re-consider the 
overwhelmingly positive attitudes regarding the “nanotechnology revolution”.  Thus, although 
potential dangers from substances used in nanomedicine are unquantified as yet, both the potential 
benefits of applications and any possible negative implications following their use have consistently 
been the subject of lively discourse at the Royal Society.  
 
 
Figure 1: Impact of particle size on the inflammatory response induced in rates following instillation 
of TiO2 particles at different doses.  From Oberdorster et al., with permission.[2]  
 
On April 30 and May 1 2014, The Royal Society of London therefore sponsored a meeting1 entitled 
“Bionano interactions, new tools insights and impacts” at Chicheley Hall2.  This 2 day session on 
bionano interactions tackled key scientific issues regarding nanotechnology applications in medicine 
and diagnostics as well as considering aspects of safety, governance and regulation of new materials, 
devices and technologies, and the capacity of existing regulatory frameworks to balance benefits, 
unquantified risks and public health.  The 54 participants in the meeting included UK and 
international academics, practicing clinicians, industry and industry organisations, an international 
legal scholar and an official representative of the Council of Europe.  Presentations and discussions 
on the first day addressed recent and prospective developments in nanomedicine that 
operationalize new, detailed understanding of bio-nano interactions. The second day focussed on 
nanosafety and regulation, asking whether bio-nanomaterials and advanced materials require new 
regulatory approaches or, in the absence of flexible regulatory frameworks already in place, does 
enhanced understanding of bio-nano interactions justify drafting  new law? 
 
Scope of the meeting 
“Bionano interactions, new tools insights and impacts” gave concrete evidence that the newest 
phase is dawning in the nanotechnology saga - the so-called fourth generation, predicted to include 
self-assembly and bioelectronics for medicines - has arrived, illustrated by state-of-the-art examples 
                                                          
1 This was a satellite meeting to the Discussion Meeting on adhesion (Cell adhesion century: culture breakthrough). 
2 https://royalsociety.org/events/2014/04/bio-nano/ 
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of nanotechnology, including self-assembly and bioelectronics for medicines as discussed below.  As 
predicted by the Royal Society over a decade before,[1] the nanotechnology revolution, offers new 
biomaterials, and better understanding and manipulation of bio-nano interactions of materials and 
cellular activity at the nanoscale, with fascinating opportunities for business and human health. An 
added value gleaned from study of nanotechnologies and nanomaterials is that these tiny materials 
allow scientists to probe cellular and tissue functioning and spotlight gaps in human knowledge.  
Indeed, several speakers highlighted the fact that getting very new ideas to a level of robust maturity 
in an emergent field can take years, especially when new knowledge and untested know-how 
challenge established norms in the medical field.  For example, the validity of in vitro models and 
approaches, which have traditionally utilised 10% calf serum protein to sustain cell cultures, was 
questioned, because the introduction of nanomaterials results in binding of these proteins to 
nanoparticle surfaces with the potential for presentation of a non-native biological identity due to 
unfolding of the proteins at the nanoparticle surface.  Across the wide range of topics discussed, the 
key underpinning concept, (whether for discrete nanoparticles or nano-structured surfaces), was the 
role of nanomaterials as scaffolds for protein / biomolecule binding (as illustrated in Figure 2) and 
the utilisation of this for targeted therapeutic delivery, electro-chemical sensing, control of stem cell 
differentiation, as well as potentially as a basis for predicting nanoparticle fate, behaviour and 
safety.  
The meeting’s central topic concerned bio-nano interactions, involving a new view of the fate and 
behaviour of nanomaterials or nanosurfaces at the interface with the biological environment. This 
“binding” or bio-interaction tendency of nanoscale surfaces results from their need to reduce their 
surface energy by binding available biomolecules,[3] and can be utilised for a range of applications at 
the interface between medicine and engineering, including diagnostic devices, nano-enabled 
therapies such as targeted drug delivery, or for tissue engineering, as summarised in Figure 3.[4]  
Indeed, biointeractions have long been understood to determine the fate of implant materials such 
as stent coatings, where integration of the device into the body requires the adsorption of a specific 
set of proteins, while binding of the wrong proteins leads to immune recognition and subsequent 
rejection of the impact.[5]  Similarly, bionano interactions and protein adsorption at nanoscale 
surfaces play key roles in cellular adhesion, mobility and phenotype development on materials 
surfaces.[6]  
 
 
Figure 2: Nanomaterials as scaffolds for protein (biomolecule) binding: nanomaterials have the right 
size and shape for interacting with transport proteins such as apoplipoproteins, offering them access 
to all cells via the LDL receptor (A).   (B) Schematic illustration of the nanoparticle corona form from 
lung surfactant proteins.  (C and D) Structure of native low-density lipoprotein (C) and synthetic 
nano low-density lipoprotein (D) designed for nanomedicine. Various compartments for loading 
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exogenous agents are shown including protein loading via covalent attachment of compounds to 
lysine amino acid residues in apoB-100 or surface loading: intercalation of amphiphilic compounds 
into the phospholipid monolayer. Core loading can also be achieved via reconstitution of 
hydrophobic compounds into the nanocarrier apolar core. From Corbin and Zheng, Nanomedicine 
2007, 2:375-380. 
 
The meeting included 12 invited lectures, 12 poster spotlights, extended discussions and 2 
rapporteur summaries.  
 
 
Figure 3: A snapshot of some application areas where nanotechnology has already had an impact in 
terms of treatment, diagnosis or imaging of some major diseases.  From the European Technology 
Platform on Nanomedicine (ETPN) White Paper 2013 "Contribution of Nanomedicine to Horizon 
2020".[4] 
 
Technical Highlights from the meeting 
 
Advances in drug delivery and mimicking biological processes: 
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Utilisation of bionano interactions as the basis for advanced drug delivery was addressed in two 
talks: 1. Matthias Epple (University of Duisburg-Essen) presented his recent work on applications of 
biodegradable multi-shell calcium phosphate (CaP) nanoparticles for delivery of DNA, proteins and 
siRNA, and 2. Rein Ulijn (University of Strathclyde) presented some new directions utilising self-
assembly of biomolecules such as peptides to drive charge transfer, an essential step in many 
biological processes such as photosynthesis and respiration. 
Calcium phosphate (CaP) nanoparticles were functionalized with the model antigen Hen Egg 
Lysozyme (HEL) to take advantage of a HEL-specific B-cell receptor transgenic mouse model. Epple 
and his team demonstrated that functionalized nanoparticles were able to effectively cross-link B-
cell receptors at the surface of antigen-matched B-cells, with the result that theywere 100-fold more 
efficient in the activation of B-cells than soluble HEL. This suggests that these are promising vaccine 
candidates for inducing humoral immunity, i.e., immunity induced by antibodies.[7]  In another 
potential application, functionalization of CaP nanoparticles with serum proteins fetuin-A and 
albumin (≥1 µM) reduced intracellular Ca2+ elevation and cell death in human vascular smooth 
muscle cells (VSMC) in response to CaP particles. Fetuin-A, a key protein whose levels are lowered in 
patients with kidney disease, also reduced dissolution of CaP particles under acidic conditions, which 
may contribute to its cytoprotective effects after CaP particle exposure to VSMCs.[8]  Thus, Epple’s 
work demonstrated the vital role played by bio-nano interactions in determining nanoparticle fate, 
behaviour and induced responses, which are all key components of effective design of drug delivery 
carriers and nanotherapeutics.  
Adaptive nanotechnology is the development of new molecular technologies using the fundamental 
principles that biology uses for adaptation (the evolutionary process whereby an organism becomes 
better able to live in its habitat) but with simpler components, such as peptides. Ulijn’s team has 
made significant progress towards understanding how catalysis and molecular self-assembly can be 
linked to produce adaptive and selective systems capable of electron transfer between 
macromolecules. For example, coupling the reversible in situ formation of a self-assembly building 
block by enzymatic condensation with biocatalytic condensation (assembly) gives rise to 
nanostructures with optimized supramolecular interactions, as evidenced by substantial aggregation 
induced emission upon assembly.  These supramolecular assemblies are capable of forming efficient 
charge-transfer complexes in the presence of suitable donors.[9] In another example, small-
molecule-based bioactive hydrogels were used as three-dimensional platforms for culturing human 
dermal fibroblasts, whereby the cells self-organized the fibrous extracellular matrix and contracted 
the gel without differentiating into myofibroblasts, in a 14-day culture.[10] Using dynamic 
nanostructures and templating or self-assembly thus provides enormous opportunities for 
developing new applications of nanotechnology, because their formation and function are driven by 
free-energy minimization, making them inherently self-healing and thus adaptive to changes in their 
surroundings.  While the current supramolecular assemblies are a long way from the clinic, one can 
envision a future whereby changes in protein or peptide content of blood plasma might trigger self-
assembly of selected peptide as the initiating step in an adaptive therapeutic response.  
 
Nanopatterned surfaces for tissue regeneration 
Utilisation of bionano interactions with nano-patterned surfaces to drive cellular behaviour was 
addressed in several presentations and from a number of different approaches including a 
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presentation on control of stem cell differentiation from Matthew Dalby (University of Glasgow) and 
of the development of synthetic biomaterials for skeletal tissue regeneration by Pamela Habibovic 
(University of Twente). 
Design of nano-patterned surfaces to control growth and differentiation of mesenchymal stem cells 
(MSC) is an important emerging area. The interaction of nanotopographical features with integrin 
receptors in the cells' focal adhesions alters how cells adhere to material surfaces, and defines 
cellular fate through changes in both cell biochemistry and cell morphology.  Depending on the scale 
of patterning, Dalby and his team found that the stem cells have quite different adhesion and 
cellular tension, with 10nm islands resulting in cellular fillopodia whereas 8nm patterning results in 
loss of fillopodia and reduced adhesion.[11]  Knowledge gained from the study of cell-
nanotopography interactions is expected to accelerate the development of next-generation stem 
cell culture materials and implant interfaces, and to fuel discovery of stem cell therapeutics to 
support regenerative therapies.[12]  Figure 4 provides a schematic illustration of some of the sorts of 
bio-nano interactions that can between nanostructured surfaces and cells and their consequences 
for cell shape, polarity and spreading. 
Consistent with these views of the significance of surface nanotopography, Habibovic spoke about 
recent approaches in her lab to improve the clinical performance of synthetic biomaterials in skeletal 
tissue regeneration. Specifically she described the use of nanotechnology methods to distinguish 
between impacts from chemical composition and those resulting from nanotopography. Habibovic 
presented a longitudinal study in which three types of biofunctionalizing surface treatments were 
compared in terms of apatite (bone) forming ability, cell attachment, cell proliferation, gene 
expression from bone tissue, bone regeneration, biomechanical stability, and bone-biomaterial 
contact.  The results suggest that the beneficial effects of cell-nanotopography modulation 
(topography) surpassed the benefits of improved bone forming ability (chemistry).[13]    
 
 
Figure 4: Summary of how differences in cell shape and polarity as well as the spreading dynamics 
are controlled by filopodia-Nanowire (NW) interactions. The first row describes for flat glass (2D) 
how fibroblasts undergo a rapid phase transition from filopodia-rich initial state towards a 
lamellipodia-mediated spreading. The second row shows how cells sitting at interfaces between flat 
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surface and NWs contact the NWs, quickly adhere, align and spread towards nanowire adhesions, 
while filopodia peel-off from the adjacent flat surfaces. After ~30 min, delayed lamellae/ruffle 
formation leads to migration towards the flat surface (Data not shown). This dynamic change in 
topography preference is reversible during mitotic rounding of fibroblasts. The bottom row shows 
how fibroblasts on purely nanowire decorated surfaces quickly spread via aligned filopodia-nanowire 
adhesions into dendritic shapes, without formation of lamellipodia. From Albuschies & Vogel, 
Scientific Reports, 2013, 3, 1658.  doi:10.1038/srep01658).   
 
Bionanointeractions to probe or manipulate cellular function 
Another aspect of manipulation of bio-nano interactions at surfaces that emerged from the meeting 
was the use nanotechnologies for enhanced understanding of cellular functioning, as exemplified by 
the talks of Jeff Karp (Harvard Medical School) who utilised targeting approaches to influence the 
behaviour of stem cells; and Frankie Rawson (University of Nottingham) who offered a clear example 
of how nanoscale tools can call into question established biological knowledge with his 
electrochemical sensing research that has shed new light on redox processes in cells and at cellular 
membranes. 
Emerging methods to induce a robust “rolling” response by engineering of the cell surface in order 
to enhance engraftment (the process of transplanted stem cells reproducing new cells) of 
systemically infused stem cells were presented.  Using a platform approach that preserves the MSC 
phenotype and does not require genetic manipulation, Karp showed how modification of the surface 
of MSCs with a nanometer-scale polymer construct (found on the surface of leukocytes) mediates 
cell rolling within inflamed tissue, thereby overcoming the problem of inadequate expression of cell 
surface adhesion receptors. A shortage of cell surface adhesion receptors has been considered a 
major limitation of existing MSC-based therapeutic approaches.[14]  Karp also discussed recent 
research using aptamers, short nucleic acid molecules with binding properties and biochemical 
characteristics that may make them suitable for use as targeting molecules, which can be conjugated 
with nanoparticles for targeted delivery and to probe cell surfaces and the cell secretome following 
transplantation. Karp presented an aptamer-based cell-surface sensor that his team developed to 
study cellular microenvironments, thus linking his presentation to.[15]   
Rawson discussed the potential use of carbon nanowires to probe charge-transfer events between 
cells and their external environment. Electrochemical sensing research from Rawson’s postdoctoral 
work used mouse macrophages, and his most recent work involves translating this knowledge to 
better understanding of electron shedding in yeast cells.  Rawson showed that vertically aligned 
single-walled carbon nanotubes (VASWCNTs) can enter cells naturally without applying external 
force; and then sense the intracellular presence of a redox active moiety, methylene blue.[16]  
Further work demonstrated the potential for the electrochemical sensing platform to monitor and 
determine the precise location of redox activities occurring within the cell,[17] and for elucidating, 
for example, the pathways via which yeast cells shed electrons with their external environment 
across the cell wall, suggesting that there is a need to redefine the function of the yeast cell wall 
(work in progress).   
 
Interactions of nanomaterials with the human body – nanosafety aspects 
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Assessing the safety of nanomedicine was the topic of two talks: 1. Howard Clark (University of 
Southampton), addressed nanoparticles entering the lung, and 2. Jonathan Powell (University of 
Cambridge) addressed uptake of nanoparticles from the gastrointestinal tract.   
Clark’s group has investigated the interaction between nanoparticles and one of the major proteins 
associated with the lung surfactant layer that allows that lungs to expand during breathing, namely 
surfactant protein D (SP-D), and the subsequent uptake of the protein-coated nanoparticles by cells 
involved in lung immunity, using a native human SP-D (NhSP-D) and a recombinant fragment SP-D 
(rfhSP-D).[18] The lung-air barrier maintains lung homeostasis (constant internal environment, via 
gas exchange and pH regulation), and is a critical part of human biological defence mechanisms, with 
surfactant protein D (SP-D) modulating pro- and anti-inflammatory processes when threatened by a 
toxic challenges.  In vivo studies investigating nanoparticle uptake by alveolar macrophages (AMs) 
and lung dendritic cells (LDCs) from control and SP-D deficient mice showed decreased uptake of 
nanoparticles in the SP-D deficient mice compared to wild-type mice, and confirmed an interaction 
between SP-D and nanoparticles, and subsequent enhanced nanoparticle uptake.[18]  Thus, 
nanoparticles can subvert the natural defence mechanisms of the lung, and may persist in the 
respiratory tract and translocate into the circulatory system, as indeed has been observed for fine 
and ultrafine particles over the last decades.   
Similarly, there are purposeful pathways for nano-mineral uptake via the gastro-intestinal tract,  
which can be hijacked by nano-scale additions to human food, toothpaste and cosmetics. Powell and 
his team investigated the toxic and inflammatory potential of two types of particles that might 
become increasingly relevant to the food industry, namely SiO₂ and ZnO. Particle pre-treatment 
under simulated gastric and intestinal pH conditions resulted in reduced acellular reactive oxygen 
species (ROS) formation but did not influence cytotoxicity (WST-1 assay) or IL-8 expression from 
human intestinal Caco-2 cells,[19] again demonstrating a critical role of bio-nano interactions. 
Interestingly, the differentiation status of the cells markedly determined the cytotoxic potency of 
the particles.[19]  The naturally occurring uptake process revolves around mineralised calcium.  
Powell showed data from recent studies demonstrating that nanoFe3+ crosses the apical surface of 
Caco-2 cells via an endocytic pathway before being dissolved in endosomes or lysosomes inside the 
cell (Figure 5), and that its subsequent homeostasis is under the normal regulatory control of dietary 
iron absorption, namely via ferroportin-dependent efflux from enterocytes.  This suggests that 
nanoFe3+ thus offers potential as a novel oral iron supplement with enhanced uptake in the nano-
form followed by release and processing in the body via the normal soluble iron pathway.[20] 
 
Figure 5:  Cellular uptake of nanoparticulate LM Fe(III) poly oxo-hydroxide by Caco-2 cells.  TEM 
images showing differentiated Caco-2 cells incubated with LM Fe(III) poly oxo-hydroxide. A, arrows 
show particle clusters adhering to the cell membrane microvilli (scale bar, 500 nm). B, arrows 
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indicate invagination on the cell membrane (scale bar, 100 nm). C and D, arrows indicate Fe 
accumulation inside the cell (scale bars: panel C, 500 nm and panel D, 100 nm).  From [20] with 
permission. 
 
Also approaching the topic from a clinical perspective, Andre Nel (University of California, Los 
Angeles) discussed existing data that supports predictive modelling and alternative testing strategies 
for regulatory decision making regarding nanomaterials.  This rapidly advancing new field requires 
novel test strategies that allow multiple toxicants to be screened in robust, mechanism-based 
assays. The notion that most investigation can be carried out at the cellular and biomolecular level 
without much animal use is based on understanding about the contribution of toxicological 
pathways to the pathophysiology of disease.[21] Nel presented the UC Centre for Environmental 
Implications of Nanotechnologies approach of selecting screening pathways on the basis of known 
physiological effects and gave examples of assessing the pulmonary hazard potential of carbon 
nanotubes[22] and metal oxides[23] using high-content or high-throughput testing and how the data 
can be used for hazard ranking, risk assessment, regulatory decision-making and 'safer-by-design' 
strategies.[21]   
Nel offered a three-tiered approach for prioritizing responses, using oxidative stress as his example: 
Tier 1 ranking the steepness of cellular dose-response curves; Tier 2 using intratracheal installation 
to assess the possibility of predicting acute inflammation from oxidative stress; and Tier 3 using 
inhalation studies about selected nanomaterials as the final verification.  As more data emerges, 
fewer materials should require progress through Tiers 2 and 3, enabling regulatory decisions to be 
justified on the basis of ATS data.[21]      
 
Policy Dilemma: Small Particles, Unknown Risks, Do We Need More Law? 
As summarized above, this meeting gave an excellent overview of the state of the art for bio-nano 
interfacial interactions in advanced materials.  Yet, perennial questions remain as to whether these 
materials represent a new threat, requiring new rules of law?  
Researchers are rushing to fill the regulatory void and therefore, associated nanosafety studies of 
new materials have developed at a dramatically rapid pace. The number of studies in the reported 
nanosafety literature has increased exponentially from one thousand articles a year to twelve 
thousand in the period 2000-2012,[24] with the concomitant effect that no scientist is prepared to 
state conclusively that their study represents the mainstream or majority view for these questions, 
even when their studies have robust methods with powerful empirical support.  With this important 
limit upon understanding from the standpoint of managing data as well as understanding risk, the 
meeting did accept the conclusion that yes, it is possible that in a very small number of cases, these 
interactions may indeed be different in character but only a few consumer items would cause such a 
concern.  New research regarding data management efforts will try to group & classify 
nanomaterials in order to support the identification of those that raise cause for concern.[25, 26]  
Control banding and techniques for categorizing groups of nanomaterials makes good sense from a 
scientific standpoint:, but does not bring decision makers closure on the underlying questions 
targeted with prescience by the Royal Commission on Environmental Pollution in 2008.[27] 
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Nanotechnology has also given a shot of adrenalin to an ailing global economy, with it’s promises of 
new medicines, lighter packaging and cheaper transport of goods, with the economic importance of 
nanotechnology estimated to be 3.5 trillion dollars by 2015.[28] Consequently, every nation and 
many regional organizations have created draft nanotechnology regulations to support research 
funding, build strategic platforms and establish performance-based regulatory goals with 
subsequent regulation of business to protect health and life at work in civil society.[29. 30]  The final 
session of the conference therefore made a pathbreaking effort to  place research advances in the 
broader policy context, and adeptly changed the focus from the laboratory bench to the judicial bar. 
This session discussed whether society can allow some nanomaterials to remain unregulated, 
whether law already exists to deal with nanotechnology applications (despite unquantified risk),  or 
whether it is a matter of simply modifying existing laws / regulatory frameworks within the context 
of civil society’s demand for safe nanoproducts and a healthy environment. 
A key area of debate for over a decade in regulatory and industry circles is whether or not “new” 
regulation and thus legislation is required for nanomaterials.  The potential for nanotechnologies to 
impact on human rights, such as health and a safe environment, has led to the Council to Europe 
assessing whether there should be guidelines or a charter on nanomaterials.[31]   Tanja Kleinsorge, 
Head of the Secretariat of the Committee on Social Affairs, Health and Sustainable Development, 
Parliamentary Assembly of the Council of Europe, offered an analysis of possible avenues for a pan-
European treaty or a series of reciprocal agreements, as recommended in the Parliamentary 
Assembly report Nanotechnology: Balancing Benefits and Risks to Public Health and the 
Environment.[31]   
Steffi Friedricks from the Nanotechnologies Industry Association suggested that there are no health 
end-points that have been reported for nanomaterials that have not previously been observed with 
chemicals.  Citing the recent paper of Prof. Ken Donaldson that called into question nanospecific 
effects (although confirming health impacts from particulate matter per se ),[32] her argument was 
that there are no “new” cytokines released in response to nanomaterials, and that while 
nanomaterials might alter the localisation and distribution of chemicals, the final impacts are well-
known, i.e. oxidative stress etc.  This led to  challenges from the audience, including a listing by Nel 
of some features of nanomaterials that are not present for chemicals / micron-scale particles, such 
as band-gap effects which for several nanomaterials have been shown to overlap with the 
conductance bands present in cells;[33] and aspect ratio for example, as well as the fact that 
chemicals do not acquire a “corona” of biomolecules or environmental macromolecules whose 
compositions depends on the surroundings,[3] and indeed this corona can evolve as the 
nanomaterials’ surroundings themselves evolve.[34]  Indeed, it is worth highlighting that even 
knowing all that we do about asbestos, there is still no single toxicology assay that would predict 
mesothelioma.  
Andrew Maynard (University of Michigan) outlined innovative approaches to emergent risks where 
he discussed the opportunities provided by nanomaterials to also develop novel frameworks for 
responsible research and innovation.  He also discussed the ideas of acceptable risk and acceptable 
safety, which need to be at the forefront of discussions, and indeed link to monetisation of risk and 
who will ultimately bear the cost of risk (i.e. insurance).  Maynard highlighted that while 
nanotechnologies have been a pioneer of responsible innovation, that some mis-steps have been 
made along the way, and that we are now a decade on in this debate.[35]  He suggested that risk 
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management strategies and regulation must be grounded in plausibility and based on concepts of 
“likely to effect” rather than “might effect”, which he illustrated as shown in Figure 6.  Thus, while 
the range of novel physico-chemical parameters is broad, not all of these will lead to novel 
mechanisms of interaction, and of those not all will lead to novel health impacts, not all of which will 
be harmful. Thus, we need to ensure that our regulatory (legal) frameworks allow for innovation and 
exploitation of the space for nanomedicine and other approaches, whilst ensuring that the small 
minority of cases that are harmful are captured and managed appropriately.  
 
 
Figure 6: Illustration of the relevant parameter space for nanoregulation and nanorisk management.  
Thus, despite the relatively large parameter space of new materials, it is likely that truly novel harm 
will occur only in very few cases.  Focussing on identifying these is critical. 
 
Analysis & integration: How can the benefits of nanotechnology applications in industry be 
realized while minimizing the unquantified risks?  
A regulatory history of dealing with the unknown or unquantified risks associated with new 
technologies is consistent with the remarks by Steffi Friedrichs, representative of the 
Nanotechnology Industries Association (NIA). As Friedrichs noted when discussing Nanosafety by 
design, only some of the regulatory challenges are nano specific: nanoenabled innovations have 
become examples of both the new vistas and the limits of existing frameworks.  Andre Nel of the 
University of California at Los Angeles (UCLA) suggested that there are several new alternative 
approaches to nanotechnology regulation, already in use in California. Nel offered his approach as a 
potential model for regulation by the US Environmental Protection Agency (EPA) and, consistent 
with the USA’s ability to create new regulatory paradigms, a possible model for global assessments.  
Ilise Feitshans (University of Lausanne), Rapporteur on policy outcomes of the meeting, outlined in 
her sum-up session the reasons that the answer is yes to all three of the regulatory questions posed 
at the meeting, i.e. are there gaps in the law, is there existing law governing nanomaterials, and will 
we have new law?  
First, many administrative agencies have attempted to stretch regulatory jurisdiction to grasp 
nanotechnology, in many places.  The question does REACH cover nanomaterials has been answered 
by the European Union itself by modifying the law to include previously considered safe materials 
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such as carbon, in the form of carbon nanotubes and graphene.[36]  So too, the US EPA has hotly 
debated regulations for nanosilver [37] and the US Food and Drug Administration (FDA) has 
attempted to regulate nanomaterials as a medical “device” without regard to the possible changes 
in chemical properties of nanoparticles due to size, and without a clear definition of nanomaterials 
involved. Second, while there are aspects of nanomaterials that may require special or new 
regulation, there are more areas that may prove to be safe and therefore additional regulations 
would be surplus, merely clogging the administrative system.[38]. Third, the reality that risks are 
unquantified has not stemmed the tide of nanoregulation: every nation and many international 
organizations have established or are drafting nanotechnology administrative schemes if for no 
other reason that the popularity of the term nanotechnology and the need to be seen by their 
populous to be taking some action.   
Feitshans observed that this policy judgment to regulate may be unfair to the fledgling 
nanotechnology applications in commerce that may later prove to have low risks, or to the 
consumers who will feel a new comfort zone because they believe that nanomaterials are regulated. 
Although the implications for bioaccumulation and nanotoxicity remain unknown, the state of the 
art of legislative drafting and litigation has progressed in the past decade, especially in the US.[39] 
Now, the real regulatory problem is the potential conflict of rapidly written laws. Noting that 
governments from the size of the municipality of Cambridge, Massachusetts in the USA to the 
Kingdom of Morocco see fit to regulate applications of nanotechnology, Feitshans emphasized that it 
is not the functionality or context of nanomaterials themselves that will be the driver for these 
policies. Furthermore, it is not a matter of excellence and forethought in legislative drafting because 
even the best written laws may not overcome a challenge based on conflicts of law.  Harmonisation 
of these laws is therefore key to good regulation. 
The result of a challenge to jurisdiction will be an admixture of contractual obligations that offer a 
choice of law to agreeing parties, principles of conflicts of law that apply internationally and political 
will. Therefore, according to Feitshans, the key issue from a regulatory standpoint has moved 
beyond the initial questions of whether to regulate, into the more complex realm of which system of 
laws will prevail in the context of globalization.  At the time of the Royal Society meeting, therefore, 
the key law and policy question that is emerging in nanotechnology is that of how to achieve global 
harmonization.  Pointing to the United Nations (UN) ‘global efforts to unify chemical safety labels, 
training and handling across every nation in a harmonized system (GHS), Feitshans suggested that 
harmonization is one form of regulation that promotes commerce, as the alternative to a swamp of 
well-intended but possibly conflicting laws, in an era of increasing globalization.[40]  She offered the 
notion that perhaps not immediately, but in the next five to ten years, nanotechnology regulators 
will become enlightened to the need for harmonization in order to make workable the best parts of 
their own system.[41]  Therefore she views as inevitable an internationally integrated unified system 
for nanotechnology regulation, whether created or opposed by the UN.[42]  
An interesting aside is that the conclusions of a recent a Royal Society report on an entirely different 
topic (that of Neuroscience and the law [43]) seem to be equally applicable to nanosafety and bio-
nano interactions and its status relative to law: simply replacing “neuro” with “nano” in the 
concluding statements from that report also summarises the current state of nanosafety, 10 years 
on from the original Royal Society report on nanotechnologies.[1]  Thus: 
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• There is big gap between research conducted by (nano)scientists and the realities of the day to 
day work of the justice system.  
• There is currently no forum in (the UK) for bringing together (nano)scientists and legal 
professionals to explore areas of mutual interest. 
• Professionals at all stages of the legal system who might encounter (nano)science should 
understand some of the key principles on which it is based; the limitations to what studies can 
tell us; and some of the generic challenges of its application.  
• Lawyers and judges in England and Wales often have no training in scientific principles. 
Undergraduates in (nano)science are not necessarily taught about the societal implications of 
the discipline.[43] 
In both situations (neuro and nano sciences), a plethora of new laws are emerging with no clear 
indicators which of those laws will become the prevailing rule.  Only a small fraction of 
nanotechnology’s emerging risks, however, can be subjected to regulation.  And, the few regulations 
that have begun to emerge are fraught with confusion, often exacerbated by litigation.[37]  There is 
a small window of opportunity for preventive use of scientific principles under law to manage risk 
and protect public health.[39].  It is therefore equally unclear, what nanotechnology will mean for 
governance at the national and international level, as government and private resources are blended 
to create new methods of regulation once global harmonization occurs.  “Nanotechnology is neither 
the first nor (hopefully!) the last such example in a long chain of precedents when humans have 
embraced new technologies mindful of risk, in the hope of furthering the progress of all humanity. 
Whether such goals can be achieved using old models for governance, or requires new approaches 
that synthesize many sets of ideals from various perspectives and from many nations, remains to be 
seen”.[29]  
 
Analysis & integration: How can the scientific community support / champion the use of scientific 
principles under law to manage risk and protect public health? 
In her summary statement, Technical Rapporteur Dr. Iseult Lynch (University of Birmingham), 
suggested that although concepts of the bio-nano interface as the mediator of nanoscale 
interactions with biology are now well established, there remains much to be done to link 
biomolecule / macromolecule coronas to health effects.  A first step in this might be to codify it, i.e. 
to move beyond lists of identified proteins to identification of functionally modified domains and 
their (signalling) implications, and then, to identify key domains that can be screened as biomarkers 
of exposure and health impacts.  Some significant progress towards this approach includes 
fingerprinting the corona of nanomaterials,[44] and understanding the impact of adsorbed protein 
conformation on receptor activation.[45]  Lynch therefore posed the question: Can we go further 
towards combinatorial and personalised medicine approaches, such as bar codes of individual health 
based on protein signatures – e.g. detect changes in protein phosphorylation for example? 
Lynch also highlighted important roadblocks to rapid progress, both for the scientific community and 
policymakers at the interface of science and policy:  There is an urgent need for agreed terminology 
in this arena, especially concerning the protein corona, its evolution and consequent ageing of the 
corona and nanomaterials themselves.  There is also a significant challenge in terms of data quality: 
with the increasing pace of publications, how can one discern the relevant from the plain wrong?  
Again, this profound dilemma is equally relevant to scientists as policy makers, regulators, and legal 
practitioners.  
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Another significant challenge is the parallel development of the fields of nanomedicine and 
nanosafety, with nanomedicine focussing primarily on the applications, and often not being fully 
cognisant of the significance of much of the emerging knowledge in the nanosafety or 
nanotoxicology arena, which has traditionally be seen as less exciting science.  This has resulted in 
many of the key findings from nanosafety research, such as the importance of detailed 
characterisation of nanomaterials in the exposure medium as the basis for realistic (including often 
non-linear) dose-response profiles,[46] the potential for dye to elute from (commercially and in-
house) fluorescently-labelled nanoparticles,[47] and the impact of particle ageing on observed 
impacts, being slow to be adopted in nanomedicine research, further proliferating poor science and 
hampering the translation of scientific principles to policy.   
One of the discussion highlights, alluded to already, relates to whether there are differences 
between nanomaterials and chemicals in terms of their impacts and thus regulatory requirements.  
From the scientific perspective, there are clear differences related to surface area (although this 
obviously includes also ambient combustion particulates) and related to manipulation of aspect 
ratio, band gap and surface strain.  Overall, there is consensus in the scientific community that the 
main challenge with nanomaterials is the convergence of multiple complexities simultaneously such 
as surface interactions (bio-nano interface), small size and thus enhanced accessibility to living 
organisms, and quantum effects,[48]  and as such understanding their behaviour, and reducing it to 
simple quantitative structure-activity relationships (QSARs) which are the basis of regulation of 
chemicals and pharmaceuticals, is non-trivial.  
Finally and related to the convergence issue, Lynch alluded to the fact that as an enabling 
technology, the uses of nanotechnologies are less confined that those of chemicals: while for 
chemicals and ultrafine particles, exposure patterns and exposed cohorts can be mapped easily, the 
presence of nanomaterials is already ubiquitous in a vast number of products (1,600+ manufacturer-
identified nanotechnology-based consumer products introduced to the market [49]). Since 
consumers are exposed via multiple routes, and even potentially regulated products are available to 
buy via the internet, occupational exposure may be less of an issue than consumer exposure in the 
future. If so, consumer exposure has very significant consequences for decisions about how we 
manage and track exposure over consumer lifetimes.  Here perhaps nanomedicine offers an 
opportunity, via tracking of nanomedical interventions in patients. 
 
 
Conclusion: The Challenges of Nanotechnology's Revolutionary Change 
The Royal Society conference “Bionano Interactions: new tools insights and impacts” provided a 
stimulating and timely look at new understanding regarding the role of bio-nano interactions and 
the interface between nanomaterials and living systems from two viewpoints:  translating potential 
nanomedicine applications into the clinic, coupled with an assessment of their safety and science-
based pathways for regulating the safety of such applications.   
Political aspects of nanotechnology embrace questions of potential liability, informed consent for 
biomedical nanotechnology applications, end-user needs to understand risk and to have access to 
information, and marketing issues pleasing consumers with attractive and informative labelling.    
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Law and science have partnered together in the recent past, to solve major public health issues.  
Historically, this partnership between law and science enables policymakers to write regulatory 
programs that incubate new industries and advance human development using new technologies, in 
the face of unknown but great risks.[50] Together, law and science have created and implemented 
policies that serve the greater social good, ranging from preventing the threat of bankruptcy in the 
asbestos industry to averting the threat of nuclear holocaust. Lessons learned from the late 
twentieth century initiatives that funded “Big Science” teach us that governments can use regulatory 
programs to supervise and promote risky new technologies, without creating a new race of 
genetically-engineered monsters or blowing up the whole world. [50] 
 
Recommendations for Action: Bringing Order to regulatory Chaos 
A prescient approach to developing nanoregulation and nano-governance frameworks will look to 
the future to the methods for creating a flexible framework for regulation that will be transnational, 
embracing many types of nanotechnology applications across industries and applying to a vast 
variety of substances, and building scientific knowledge into the process.   
Harmonizing law of nanotechnology is important because commerce will be paralysed by the conflict 
of law.  The best approach will harmonize many laws from several nations, as well as across 
disciplines such as environmental sciences, toxicology, medicine, and public health. To be effective, 
this approach will be transparent because effective systems require stakeholder participation, in 
order to create workable laws that will address emerging risks without blocking the growth of 
invaluable new industries and commerce.  
Categorization of scientific data regarding the positive and negative impacts of nanotechnologies in 
a range of applications must be prioritised, as a sensible nanoinformatics framework is a logical next 
step in the development of applications for nanotechnology to benefit civil society.   
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Figure captions (numbered in sequence as they appear in the text)  
 
Figure 1: Impact of particle size on the inflammatory response induced in rates following instillation 
of TiO2 particles at different doses.  From Oberdorster et al., with permission.[2]  
 
Figure 2: Nanomaterials as scaffolds for protein (biomolecule) binding: nanomaterials have the right 
size and shape for interacting with transport proteins such as apoplipoproteins, offering them access 
to all cells via the LDL receptor (A).   (B) Schematic illustration of the nanoparticle corona form from 
lung surfactant proteins.  (C and D) Structure of native low-density lipoprotein (C) and synthetic 
nano low-density lipoprotein (D) designed for nanomedicine. Various compartments for loading 
exogenous agents are shown including protein loading via covalent attachment of compounds to 
lysine amino acid residues in apoB-100 or surface loading: intercalation of amphiphilic compounds 
into the phospholipid monolayer. Core loading can also be achieved via reconstitution of 
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hydrophobic compounds into the nanocarrier apolar core. From Corbin and Zheng, Nanomedicine 
2007, 2:375-380. 
 
Figure 3: A snapshot of some application areas where nanotechnology has already had an impact in 
terms of treatment, diagnosis or imaging of some major diseases.  From the European Technology 
Platform on Nanomedicine (ETPN) White Paper 2013 "Contribution of Nanomedicine to Horizon 
2020".[4] 
 
Figure 4: Summary of how differences in cell shape and polarity as well as the spreading dynamics 
are controlled by filopodia-Nanowire (NW) interactions. The first row describes for flat glass (2D) 
how fibroblasts undergo a rapid phase transition from filopodia-rich initial state towards a 
lamellipodia-mediated spreading. The second row shows how cells sitting at interfaces between flat 
surface and NWs contact the NWs, quickly adhere, align and spread towards nanowire adhesions, 
while filopodia peel-off from the adjacent flat surfaces. After ~30 min, delayed lamellae/ruffle 
formation leads to migration towards the flat surface (Data not shown). This dynamic change in 
topography preference is reversible during mitotic rounding of fibroblasts. The bottom row shows 
how fibroblasts on purely nanowire decorated surfaces quickly spread via aligned filopodia-nanowire 
adhesions into dendritic shapes, without formation of lamellipodia. From Albuschies & Vogel, 
Scientific Reports, 2013, 3, 1658.  doi:10.1038/srep01658).   
 
Figure 5:  Cellular uptake of nanoparticulate LM Fe(III) poly oxo-hydroxide by Caco-2 cells.  TEM 
images showing differentiated Caco-2 cells incubated with LM Fe(III) poly oxo-hydroxide. A, arrows 
show particle clusters adhering to the cell membrane microvilli (scale bar, 500 nm). B, arrows 
indicate invagination on the cell membrane (scale bar, 100 nm). C and D, arrows indicate Fe 
accumulation inside the cell (scale bars: panel C, 500 nm and panel D, 100 nm).  From [20] with 
permission. 
 
Figure 6: Illustration of the relevant parameter space for nanoregulation and nanorisk management.  
Thus, despite the relatively large parameter space of new materials, it is likely that truly novel harm 
will occur only in very few cases.  Focussing on identifying these is critical. 
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